Yahoo
Shanghai - Delayed Quote CNY

CanSino Biologics Inc. (688185.SS)

72.75 -1.05 (-1.42%)
At close: October 30 at 3:00:00 PM GMT+8
Chart Range Bar
Loading chart for 688185.SS
  • Previous Close 73.80
  • Open 74.00
  • Bid 72.75 x --
  • Ask 72.76 x --
  • Day's Range 70.68 - 79.23
  • 52 Week Range 46.89 - 108.00
  • Volume 9,348,826
  • Avg. Volume 8,858,249
  • Market Cap (intraday) 17.972B
  • Beta (5Y Monthly) 1.13
  • PE Ratio (TTM) 454.69
  • EPS (TTM) 0.16
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Aug 23, 2022
  • 1y Target Est 84.00

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

cansinotech.com

1,134

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

688185.SS
15.75%
HANG SENG INDEX (^HSI)
9.11%

1-Year Return

688185.SS
3.92%
HANG SENG INDEX (^HSI)
11.37%

3-Year Return

688185.SS
7.67%
HANG SENG INDEX (^HSI)
33.83%

5-Year Return

688185.SS
73.30%
HANG SENG INDEX (^HSI)
8.21%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 332.48M
Earnings 17.01M
Profit Margin 5.12%

Q2

FY25

Q3

FY25

Q2

FY26

Q3

FY26

0
100M
200M
300M
10.0%
20.0%
30.0%
40.0%
50.0%

Analyst Insights

View More

Analyst Price Targets

84.00
84.00 Average
72.75 Current
84.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.36%

  • Return on Assets (ttm)

    -0.60%

  • Return on Equity (ttm)

    0.60%

  • Revenue (ttm)

    1.26B

  • Net Income Avi to Common (ttm)

    29.72M

  • Diluted EPS (ttm)

    0.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.78B

  • Total Debt/Equity (mrq)

    18.56%

  • Levered Free Cash Flow (ttm)

    -401.33M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: